
Abstract Background and Aims The triggering factors of sepsis-induced myocardial dysfunction (SIMD) are poorly understood and are not addressed by current treatments. S100A8/A9 is a pro-inflammatory alarmin abundantly secreted by activated neutrophils during infection and inflammation. We investigated the efficacy of S100A8/A9 blockade as a potential new treatment in SIMD. Methods The relationship between plasma S100A8/A9 and cardiac dysfunction was assessed in a cohort of 62 patients with severe sepsis admitted to the intensive care unit of Linköping University Hospital, Sweden. We used S100A8/A9 blockade with the small-molecule inhibitor ABR-238901 and S100A9−/− mice for therapeutic and mechanistic studies on endotoxemia-induced cardiac dysfunction in mice. Results In sepsis patients, elevated plasma S100A8/A9 was associated with left-ventricular (LV) systolic dysfunction and increased SOFA score. In wild-type mice, 5 mg/kg of bacterial lipopolysaccharide (LPS) induced rapid plasma S100A8/A9 increase and acute LV dysfunction. Two ABR-238901 doses (30 mg/kg) administered intraperitoneally with a 6 h interval, starting directly after LPS or at a later time-point when LV dysfunction is fully established, efficiently prevented and reversed the phenotype, respectively. In contrast, dexamethasone did not improve cardiac function compared to PBS-treated endotoxemic controls. S100A8/A9 inhibition potently reduced systemic levels of inflammatory mediators, prevented upregulation of inflammatory genes and restored mitochondrial function in the myocardium. The S100A9−/− mice were protected against LPS-induced LV dysfunction to an extent comparable with pharmacologic S100A8/A9 blockade. The ABR-238901 treatment did not induce an additional improvement of LV function in the S100A9−/− mice, confirming target specificity. Conclusion Elevated S100A8/A9 is associated with the development of LV dysfunction in severe sepsis patients and in a mouse model of endotoxemia. Pharmacological blockade of S100A8/A9 with ABR-238901 has potent anti-inflammatory effects, mitigates myocardial dysfunction and might represent a novel therapeutic strategy for patients with severe sepsis. Graphical Abstract
ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::inflamación, Lipopolysaccharides, S100A8/A9; Sepsis-induced myocardial dysfunction; Endotoxemia; Mitochondrial function; Inflammation; Neutrophils, Heart Diseases, Neutrophils, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas, Mice, Ventricular Dysfunction, Left, Kardiologi och kardiovaskulära sjukdomar, S100A8/A9, Animals, Humans, Calgranulin B, Calgranulin A, Septicèmia, Inflammation, DISEASES::Cardiovascular Diseases::Heart Diseases, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Sepsis-induced myocardial dysfunction, DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation::Systemic Inflammatory Response Syndrome::Sepsis, RC86-88.9, Research, Myocardium, Medical emergencies. Critical care. Intensive care. First aid, Inflamació, Endotoxemia, Cor - Malalties - Tractament, ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::inflamación::síndrome de respuesta inflamatoria sistémica::sepsis, Mitochondrial function, Cardiology and Cardiovascular Disease, DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation
ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::inflamación, Lipopolysaccharides, S100A8/A9; Sepsis-induced myocardial dysfunction; Endotoxemia; Mitochondrial function; Inflammation; Neutrophils, Heart Diseases, Neutrophils, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ENFERMEDADES::enfermedades cardiovasculares::enfermedades cardíacas, Mice, Ventricular Dysfunction, Left, Kardiologi och kardiovaskulära sjukdomar, S100A8/A9, Animals, Humans, Calgranulin B, Calgranulin A, Septicèmia, Inflammation, DISEASES::Cardiovascular Diseases::Heart Diseases, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Sepsis-induced myocardial dysfunction, DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation::Systemic Inflammatory Response Syndrome::Sepsis, RC86-88.9, Research, Myocardium, Medical emergencies. Critical care. Intensive care. First aid, Inflamació, Endotoxemia, Cor - Malalties - Tractament, ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::inflamación::síndrome de respuesta inflamatoria sistémica::sepsis, Mitochondrial function, Cardiology and Cardiovascular Disease, DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 52 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
